Skip to main content
OpenTrials
Completed

NCT Number: NCT05433090

An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies

This is a pilot study to assess the preliminary efficacy of an inpatient advance care planning intervention on outcomes in older patients with hematologic malignancies

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hematologic Malignancies Hematologic Diseases Hematologic Neoplasms Hemic and Lymphatic Diseases Neoplasms Neoplasms by Site

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Rochester

Rochester, New York, 14642, United States

About this study

Older adults with hematologic malignancies receive more aggressive inpatient care at the end of life compared to patients with solid tumors. Advance care planning may promote early serious illness conversations for patients with hematologic malignancies, leading to less aggressive healthcare utilization at the end of life. This pilot aims to assess the preliminary efficacy of an inpatient advance care planning intervention on outcomes in older patients with hematologic malignancies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥60 years
  • A diagnosis of hematologic malignancy [including but not limited to acute leukemia, myeloid malignancies (e.g., atypical CML, MDS/MPN overlap syndromes, CMML), multiple myeloma, lymphoma, or any other hematologic malignancies based on the primary oncologist's judgment]
  • Able to provide informed consent
  • Being managed in the inpatient setting
  • English-speaking

Exclusion criteria

  • None

Treatment and study plan

Inpatient serious illness care program

Behavioral

Inpatient advance care planning intervention that will be delivered by advanced care practitioners or hematology/oncology fellow physicians. The intervention will be an adapted version of the serious illness care program.

Primary outcomes

  1. Retention Rate

    Time frame: From consent until completion of the ACP intervention visit, usually within 1 week.

    Retention rate is the percentage of consented patients who completed the ACP intervention visit. A retention rate of >70% was considered feasible.

Secondary outcomes

  1. Advance Directive Completion - HCP

    Time frame: From baseline (pre-intervention) to 1 year post-intervention. The time interval is approximately 1 year.

    Data on the patient's completion of scanned healthcare proxy form that was completed with their physician was collected via the electronic medical record. This is expressed as a percentage.

  2. Advance Directive Completion - MOLST

    Time frame: From baseline (pre-intervention) to 1 year post-intervention. The time interval is approximately 1 year.

    Data on the patient's completion of scanned medical order for life sustaining treatment (MOLST) form that was completed with their clinician was collected via the electronic medical record. This is expressed as a percentage.

Sponsors and collaborators

Lead sponsor

University of Rochester

Other

Registry information

Acronym: Inpatient SICP

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Jun 27, 2022
Registry last updated
Mar 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.